MedTrace Logo

A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma

NCT03334708 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 700

Last updated 2025-12-02

No results posted yet for this study

Summary

The purpose of this study is to develop a minimally invasive test to diagnose pancreatic cancer at early stages of disease and monitor response to treatment.

Conditions

Interventions

DIAGNOSTIC_TEST

Blood Draw

If clinically safe, up to approximately 50ml of blood will be drawn, not to exceed the following criteria: Patients and controls weighing 50kg or more * For draw amounts up to 50mL, there is no required hemoglobin threshold. * For amounts exceeding 50mL, patients who meet standard blood banking criteria (e.g., hemoglobin values within normal limits and minimum weight of 50kg) may give as much as a full unit of blood (500mL) at one time or in divided fractions over a 56 day/eight week period. Patients and controls weighing \< 50kg * For patients whose hemoglobin is below normal limits but at least 7.0 gm/dL, no more than a total of 50 ml of blood or 5 ml/kg, whichever is less, may be collected per 56 day/eight week period, but no more than approximately 2 ml/kg of blood at any one time.

DIAGNOSTIC_TEST

Tumor Tissue Collection

Tumor tissue will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere

DIAGNOSTIC_TEST

Cyst Fluid

Cyst fluid will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere

Sponsors & Collaborators

  • Sheba Medical Center

    collaborator OTHER_GOV

  • Weill Medical College of Cornell University

    collaborator OTHER

  • Weizmann Institute of Science

    collaborator OTHER

  • Memorial Sloan Kettering Cancer Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-30
Primary Completion
2026-10-30
Completion
2026-10-30

Countries

  • United States
  • Israel

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03334708 on ClinicalTrials.gov